Bharat Parenterals Limited

BSE: 541096 NSE: BPLPHARMA
Bharat Parenterals Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials & compliance.
CIN L24231GJ1992PLC018237 Incorporated 03 September 1992 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - NSE: BPLPHARMA · BSE: 541096 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹1,224 Cr
BPLPHARMA · NSE
Share Price
₹1,690.00
-4.84% today
Revenue
₹345 Cr
FY 2025-26 · +1.5% YoY
EBITDA
₹15.82 Cr
Margin 4.6%
Net Profit
−₹8.47 Cr
FY 2025-26 · +29.1% YoY
ROE
-8.4%
ROCE -1.8%
Debt / Equity
0.50
Interest cover -68.0x
Authorised capital
₹8 Cr
Registered with MCA

About Bharat Parenterals Limited

Data last updated:

Bharat Parenterals Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 September 1992 and has been in existence for over 34 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1992PLC018237. Its GSTIN is 24AAACB8636N1ZE (Gujarat). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 541096 and NSE: BPLPHARMA.

The company has an authorised share capital of ₹8 Cr and a paid-up capital of ₹6.89 Cr. It is led by directors including Bharatkumar Rameshchandra Desai (Managing Director) and Hemang Jayendrabhai Shah.

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹345.43 Cr, a growth of 1.5% compared to the previous year. For the same year it recorded a net loss of ₹8.47 Cr (net margin -2.5%) and EBITDA of ₹15.82 Cr (EBITDA margin 4.6%). The net worth stands at ₹322.23 Cr (down 2.6% YoY). Total assets are valued at ₹480.22 Cr (down 9.5% YoY).

The company has about 396 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Bharat Parenterals. As per MCA filings, the company has open charges of ₹145.09 Cr and satisfied charges of ₹34.12 Cr on record. Court records list 157 cases involving the company, including 120 filed by the company and 38 filed against it; 40 cases are pending. The company has 1 deal on record (1 market trade); the latest was in February 2025. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Kopran Research Laboratories Limited with revenue of ₹365.89 Cr. The company has 15 MSME Form 1 returns on record between 2019 and 2023, listing 2,680 overdue payments to 286 micro and small suppliers.

Bharat Parenterals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-24-0005108). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bplindia.in.

Company details

CIN L24231GJ1992PLC018237
Registration Number 018237
Incorporation Date 03 September 1992
ROC Ahmedabad
Listing Status Listed - Listed on NSE (BPLPHARMA); Listed on BSE (541096)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-24-0005108

CIN history

Bharat Parenterals has one previous CIN (Corporate Identification Number): U24231GJ1992PLC018237. The current CIN is L24231GJ1992PLC018237, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231GJ1992PLC018237Current
U24231GJ1992PLC018237Previous
Key People
Bharatkumar Rameshchandra Desai Managing Director Hemang Jayendrabhai Shah Director Shaileshkumar Gabhawala Director

Recognitions & Rankings of Bharat Parenterals

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-GJ-24-0005108

Contact details

Bharat Parenterals Limited's registered office is in Vadodara, Gujarat. Its website is bplindia.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    bplindia.in
  • Social Media
  • Registered Address
    Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Bharat Parenterals Limited, buy the company report.

Comprehensive company report
Bharat Parenterals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Bharat Parenterals operates one associated brand: Bharat Parenterals. Each brand links to its own profile.

BrandDescriptionWebsite
Bharat Parenterals
Pharmaceutical formulations are manufactured for domestic and international markets.bplindia.in

Business activity

The main business activity of Bharat Parenterals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Bharat Parenterals Limited, buy the company report.

Financials of Bharat Parenterals Limited

FY 2025-26 filings available

Bharat Parenterals Limited reported revenue of ₹345.43 Cr (up 1.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹345 Cr
+1.5% YoY
EBITDA
₹15.82 Cr
+488.1% YoY
Profit After Tax
−₹8.47 Cr
+29.1% YoY
Net Worth
₹322 Cr
-2.6% YoY
Total Assets
₹480 Cr
-9.5% YoY
Total Debt
₹146 Cr
-18.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue345340261218212205228
Revenue growth+1.5%+30.3%+19.8%+2.8%+3.6%-10.3%-
EBITDA15.822.6927.0920.2828.0625.2428.06
EBITDA margin+4.6%+0.8%+10.4%+9.3%+13.2%+12.3%+12.3%
Profit before tax(21.42)(33.96)18.7323.5427.8727.1132.80
Net profit(8.47)(11.94)14.5716.1521.5720.1524.44
Net profit margin-2.5%-3.5%+5.6%+7.4%+10.2%+9.9%+10.7%
EPS (₹)(11.88)(18.32)24.9428.4736.4635.5942.14
Balance sheet
Total assets480531399269189157120
Net worth322331197183166144118
Total debt14618015849.7417.7512.241.30
Cash & bank11.9357.5914.529.984.682.4310.40
Net working capital17223315710395.9765.2566.31
Cash flow
Cash from operations38.36(27.25)(4.71)21.66(1.07)24.4514.45
Cash from investing9.32(137)(105)(77.82)(6.63)(43.37)(12.60)
Cash from financing(47.05)15611060.609.4210.50(2.82)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue93.7499.6265.1964.6211610472.2671.63
Revenue growth (YoY)-19.2%-4.2%-9.8%-9.8%+25.4%---
Other income1.113.631.333.531.061.932.944.21
EBITDA8.54(0.53)1.740.8213.782.233.64(7.66)
EBITDA margin+9.1%-0.5%+2.7%+1.3%+11.9%+2.1%+5.0%-10.7%
Depreciation8.698.638.468.568.608.528.769.01
Interest2.452.852.903.113.693.943.332.91
Profit before tax(1.49)(8.38)(8.29)(7.32)2.55(8.30)(5.51)(15.37)
Tax2.07(0.21)1.391.293.411.132.372.14
Net profit(3.56)(8.17)(9.68)(8.61)(0.86)(9.43)(7.88)(17.51)
EPS (₹)(5.17)(11.84)(14.03)(12.48)(1.27)(14.40)(11.42)(27.00)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue234304258218212204226
Revenue growth-23.1%+17.9%+18.4%+2.8%+4.1%-10.0%-
EBITDA21.1033.6032.9421.7428.5525.1330.22
EBITDA margin+9.0%+11.1%+12.8%+10.0%+13.5%+12.3%+13.4%
Profit before tax21.8536.3130.7832.1628.3627.0134.96
Net profit15.8027.1622.6019.7821.8220.0426.61
Net profit margin+6.8%+8.9%+8.8%+9.1%+10.3%+9.8%+11.8%
EPS (₹)23.2438.3838.8242.1436.8935.2745.90
Balance sheet
Total assets424454300238182157125
Net worth402387214191166144123
Total debt20.0764.7483.0245.7115.0112.241.30
Cash & bank7.3927.785.097.434.612.169.99
Net working capital12417113310596.9267.7971.03
Cash flow
Cash from operations44.5719.22(0.16)(11.56)(22.08)29.6714.48
Cash from investing4.14(89.69)(38.19)(13.95)21.76(46.27)(12.60)
Cash from financing(48.80)69.2533.5128.522.248.31(3.07)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue55.5056.5441.4141.7094.3780.2867.3464.45
Revenue growth (YoY)-41.2%-29.6%-38.5%-35.3%+2.5%---
Other income1.054.442.284.211.622.263.794.60
Total expenses48.6856.5037.9439.3779.1175.6958.9958.79
EBITDA6.820.043.472.3315.264.598.355.66
EBITDA margin+12.3%+0.1%+8.4%+5.6%+16.2%+5.7%+12.4%+8.8%
Depreciation2.262.042.102.172.061.821.861.75
Interest0.690.510.550.961.421.481.410.88
Profit before tax4.921.933.103.4113.403.558.877.63
Tax1.280.551.180.693.401.282.362.14

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue93.7499.6265.1964.6211610472.2671.63
Revenue growth (YoY)-19.2%-4.2%-9.8%-9.8%+25.4%---
Other income1.113.631.333.531.061.932.944.21
EBITDA8.54(0.53)1.740.8213.782.233.64(7.66)
EBITDA margin+9.1%-0.5%+2.7%+1.3%+11.9%+2.1%+5.0%-10.7%
Depreciation8.698.638.468.568.608.528.769.01
Interest2.452.852.903.113.693.943.332.91
Profit before tax(1.49)(8.38)(8.29)(7.32)2.55(8.30)(5.51)(15.37)
Tax2.07(0.21)1.391.293.411.132.372.14
Net profit(3.56)(8.17)(9.68)(8.61)(0.86)(9.43)(7.88)(17.51)
EPS (₹)(5.17)(11.84)(14.03)(12.48)(1.27)(14.40)(11.42)(27.00)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue345340261218212205228
Revenue growth+1.5%+30.3%+19.8%+2.8%+3.6%-10.3%-
Other income9.5411.624.6811.747.788.6711.48
Total expenses330338234198184179200
Employee cost67.2849.6622.7918.0015.3714.7515.58
EBITDA15.822.6927.0920.2828.0625.2428.06
EBITDA margin+4.6%+0.8%+10.4%+9.3%+13.2%+12.3%+12.3%
Depreciation34.2535.329.025.886.666.035.88
Interest12.5312.954.022.601.310.770.86
Profit before tax(21.42)(33.96)18.7323.5427.8727.1132.80
Tax5.889.728.217.837.076.818.65
Net profit(8.47)(11.94)14.5716.1521.5720.1524.44
Net profit margin-2.5%-3.5%+5.6%+7.4%+10.2%+9.9%+10.7%
EPS (₹)(11.88)(18.32)24.9428.4736.4635.5942.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital6.896.895.825.775.775.735.73
Reserves & surplus315324191177160138112
Shareholders' funds (net worth)322331197183166144118
Minority interest(10.65)8.3340.9135.104.32(0.05)0.00
Secured loans14217515546.9412.539.781.30
Unsecured loans4.285.042.552.805.222.460.00
Total debt14618015849.7417.7512.241.30
Total liabilities480531399269189157120
Assets
Gross block35932425781.5774.4872.5555.08
Net block25525221142.1840.8444.5633.06
Capital work in progress35.2231.2624.9499.0125.650.4412.16
Investments6.104.980.000.0011.4842.790.01
Inventories84.7271.9561.4737.8420.7622.4328.82
Sundry debtors15117214111273.4067.8379.35
Cash & bank balances11.9357.5914.529.984.682.4310.40
Loans & advances57.7849.2544.5924.0533.4112.5413.04
Total current assets305351262184132105132
Total current liabilities13311810580.9736.2839.9865.30
Net working capital17223315710395.9765.2566.31
Total assets480531399269189157120
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.568.717.843.401.6810.1011.07
Net cash from operating activities38.36(27.25)(4.71)21.66(1.07)24.4514.45
Net cash from investing activities9.32(137)(105)(77.82)(6.63)(43.37)(12.60)
Net cash from financing activities(47.05)15611060.609.4210.50(2.82)
Net change in cash0.64(8.27)0.944.441.72(8.43)(0.96)
Closing cash11.9357.5914.529.984.682.4310.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.5%+30.3%+19.8%+2.8%+3.6%-10.3%-
EBITDA growth+488.1%-90.1%+33.6%-27.7%+11.2%-10.1%-
PBT growth+36.9%--20.4%-15.5%+2.8%-17.4%-5.2%
Net income growth+29.1%-182.0%-9.8%-25.1%+7.1%-17.6%-
Revenue CAGR (3Y)+16.6%+17.1%+8.5%-1.5%-1.2%+14.4%+27.0%
EBITDA CAGR (3Y)-8.0%-54.2%+2.4%-10.3%-1.0%+27.5%+62.8%
Profitability & leverage
Net income margin-7.9%-12.8%+4.0%+7.2%+9.8%+9.9%+10.6%
Return on capital employed-1.8%-4.8%+7.7%+12.5%+17.1%+20.2%+30.7%
Return on net worth-8.4%-16.6%+5.5%+9.0%+13.4%+15.5%+22.8%
Debt / equity0.500.640.550.190.100.050.03
Long-term debt / equity0.320.290.220.060.060.040.01
Interest cover-67.99-39.6922.2518.066.124.013.88
Efficiency & per share
Fixed asset turnover1.011.171.542.792.883.214.28
Inventory turnover4.415.105.267.449.827.998.89
Debtors turnover2.142.172.062.353.002.783.19
EPS (₹)(11.88)(18.32)24.9428.4736.4635.5942.14
Dividend per share (₹)1.001.001.000.750.000.000.00
Book value per share (₹)467.55479.79338.96316.55287.16251.09206.27
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue55.5056.5441.4141.7094.3780.2867.3464.45
Revenue growth (YoY)-41.2%-29.6%-38.5%-35.3%+2.5%---
Other income1.054.442.284.211.622.263.794.60
Total expenses48.6856.5037.9439.3779.1175.6958.9958.79
EBITDA6.820.043.472.3315.264.598.355.66
EBITDA margin+12.3%+0.1%+8.4%+5.6%+16.2%+5.7%+12.4%+8.8%
Depreciation2.262.042.102.172.061.821.861.75
Interest0.690.510.550.961.421.481.410.88
Profit before tax4.921.933.103.4113.403.558.877.63
Tax1.280.551.180.693.401.282.362.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue234304258218212204226
Revenue growth-23.1%+17.9%+18.4%+2.8%+4.1%-10.0%-
Other income12.5514.558.0418.847.788.6711.48
Total expenses213271225196183179196
Employee cost25.1321.3819.6216.9315.2614.3914.11
EBITDA21.1033.6032.9421.7428.5525.1330.22
EBITDA margin+9.0%+11.1%+12.8%+10.0%+13.5%+12.3%+13.4%
Depreciation8.367.056.405.856.666.035.88
Interest3.444.793.802.571.310.760.86
Profit before tax21.8536.3130.7832.1628.3627.0134.96
Tax5.839.868.217.837.076.818.65
Net profit15.8027.1622.6019.7821.8220.0426.61
Net profit margin+6.8%+8.9%+8.8%+9.1%+10.3%+9.8%+11.8%
EPS (₹)23.2438.3838.8242.1436.8935.2745.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital6.896.895.825.775.775.735.73
Reserves & surplus395380208185160138117
Shareholders' funds (net worth)402387214191166144123
Secured loans20.0764.7483.0242.9112.5312.241.30
Unsecured loans0.000.000.002.802.480.000.00
Total debt20.0764.7483.0245.7115.0112.241.30
Total liabilities424454300238182157125
Assets
Gross block97.9886.5783.4075.6274.4872.5555.08
Net block50.5446.1839.3636.2640.8444.5633.06
Capital work in progress5.525.000.000.000.620.0012.16
Investments19516848.6138.4016.3041.820.26
Inventories54.3346.8554.4337.8420.7622.4327.69
Sundry debtors12116514011273.4067.8381.70
Cash & bank balances7.3927.785.097.434.612.169.99
Loans & advances36.9726.4321.0116.8433.1112.8116.79
Total current assets219266220175132105136
Total current liabilities95.4594.9287.6369.5234.9637.4465.14
Net working capital12417113310596.9267.7971.03
Total assets424454300238182157125
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.341.436.343.331.409.6910.88
Net cash from operating activities44.5719.22(0.16)(11.56)(22.08)29.6714.48
Net cash from investing activities4.14(89.69)(38.19)(13.95)21.76(46.27)(12.60)
Net cash from financing activities(48.80)69.2533.5128.522.248.31(3.07)
Net change in cash(0.10)(1.21)(4.84)3.011.93(8.29)(1.19)
Closing cash7.3927.785.097.434.612.169.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-23.1%+17.9%+18.4%+2.8%+4.1%-10.0%-
EBITDA growth-37.2%+2.0%+51.5%-23.9%+13.6%-16.8%-
PBT growth-39.8%+18.0%-4.3%+13.4%+5.0%-22.7%-2.7%
Net income growth-41.8%+20.2%+14.3%-9.4%+8.9%-24.7%-
Revenue CAGR (3Y)+2.4%+12.8%+8.2%-1.3%-1.2%+14.3%+26.7%
EBITDA CAGR (3Y)-1.0%+5.6%+9.4%-10.4%-1.9%+24.0%+62.8%
Profitability & leverage
Net income margin+6.9%+8.7%+8.8%+11.2%+10.0%+9.9%+11.6%
Return on capital employed+5.7%+10.9%+12.9%+13.6%+17.5%+19.7%+31.6%
Return on net worth+4.1%+8.8%+11.2%+11.1%+13.7%+15.1%+23.9%
Debt / equity0.110.240.320.170.090.050.03
Long-term debt / equity0.020.010.020.050.060.030.01
Interest cover27.0018.0414.3216.175.983.983.53
Efficiency & per share
Fixed asset turnover2.543.583.563.373.283.194.24
Inventory turnover4.636.016.148.6311.168.139.28
Debtors turnover1.642.002.252.723.412.723.07
EPS (₹)23.2438.3838.8242.1436.8935.2745.90
Dividend per share (₹)1.001.001.000.750.000.000.00
Book value per share (₹)583.78561.27367.05330.86287.72251.22214.92

To see the full year-wise statements and ratios of Bharat Parenterals Limited, buy the company report.

Board of directors of Bharat Parenterals Limited

Bharat Parenterals has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Hemang Jayendrabhai ShahDirector08 Jul 201016 Years 3 MonthsCurrent
Shaileshkumar Gabhawala
Also directs: S.L. Infrabuildcon Private Limited
Director03 Aug 20179 Years 2 MonthsCurrent
Mukeshbhai Jivrajbhai Patel
Also directs: Agroxa Bio Innovations LLP, Innoxel Lifesciences Private Limited, Agriland Biotech Limited
Director26 Sep 20206 Years 0 MonthsCurrent
Bharatkumar Rameshchandra Desai
Also directs: Innoxel Lifesciences Private Limited, Pharmaceuticals Export Promotion Council of India, Varenyam Biolifesciences Private Limited
Managing Director03 Sep 199234 Years 1 MonthsCurrent
Zankhana Bimalkumar Sheth
Also directs: Innoxel Lifesciences Private Limited
Director14 Aug 20188 Years 2 MonthsCurrent
Alkesh Jayantilal ShahDirector28 Jul 20251 Years 2 MonthsCurrent
View all directors

Peer comparison

Bharat Parenterals Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Kopran Research Laboratories Limited₹365.89 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Geltec Private Limited₹362.73 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Mepro Pharmaceuticals Private Limited₹356.46 Cr (FY 2025)20.0%Surendra Nagar, Gujarat, India
Geno Pharmaceuticals Private Limited₹349.47 Cr (FY 2025)14.0%Goa, India
Sparsh Bio-Tech Private Limited₹346.49 Cr (FY 2025)-29.0%Jamnagar, Gujarat, India
Bharat Parenterals Limitedthis company₹345.43 Cr (FY 2026)-₹8.47 Cr-2.5%1.5%396Vadodara, Gujarat, India
Capsugel Healthcare Private Limited₹340.69 Cr (FY 2025)9.0%Gurugram, Haryana, India
Walter Bushnell Enterprises Private Limited₹340.47 Cr (FY 2025)132.0%Mumbai, Maharashtra, India
Ozone Pharmaceuticals Limited₹337.45 Cr (FY 2025)-1.0%New Delhi, Delhi, India

To see the full peer comparison of Bharat Parenterals Limited, buy the company report.

Auditor

Bharat Parenterals Limited is audited by Shah Mehta & Bakshi for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Shah Mehta & BakshiFY 2025103824W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 67.20%, foreign institutional investors hold 0.10%, domestic institutional investors hold 1.40% and retail and other public shareholders hold 31.30%.

Promoters: 67.20%DII (Domestic Institutional): 1.40%FII (Foreign Institutional): 0.10%Retail & Others: 31.30%
Sep 2026
QUARTER
67.20% Promoters
1.40% DII (Domestic Institutional)
0.10% FII (Foreign Institutional)
31.30% Retail & Others
Promoter holding - history
Now 67.20% · Sep 2026High 67.20% · Dec 2025Low 67.20% · Dec 2025
66%66.8%67.5%68.3%69%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 67.20%Mar 2026: 67.20%Jun 2026: 67.20%Sep 2026: 67.20%67.20%67.20%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters67.20%67.20%67.20%67.20%
Public32.80%32.80%32.80%32.80%

Charges & borrowings

Open charges
₹145.09 Cr
Satisfied charges
₹34.12 Cr
Breakdown by lending institutions
Axis Bank Limited₹129.59 Cr
Sidbi₹12.00 Cr
Hdfc Bank Limited₹2.04 Cr
Others₹1.39 Cr
Axis Bank Ltd₹0.08 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
16 Feb 2026101250276Others₹1.39 CrOpen
17 Dec 2025101209961Sidbi₹12 CrOpen
26 Nov 2025101189310Hdfc Bank Limited₹12.86 LakhOpen
16 Dec 2024101015285Hdfc Bank Limited₹21.5 LakhOpen
21 Sep 2024100978023Hdfc Bank Limited₹78 LakhOpen

To see the full charge records of Bharat Parenterals Limited, buy the company report.

Total charge records: 40 View all charges

Deals & funding

Bharat Parenterals Limited has 1 deal on record (1 market trade); the latest was in February 2025.

Total deals
1
Market trade
1

Deals on record (1 of 1)

WhenDealAmountParties
Feb 2025Market trade₹6.61 CrBuyer: Setu Securities Private Limited
Seller: Neo Apex Share Broking Services LLP

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Bharat Parenterals Limited has 15 MSME Form 1 returns on record between 2019 and 2023, listing 2,680 overdue payments to 286 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 286)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
Paras Offset
Mahavir Syspower Private Limited
B T Water Treatment Private Limited

To see the full MSME payment records of Bharat Parenterals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Bharat Parenterals has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
1
Associated companies
Key subsidiaries
Company NameCINShares held
Innoxel Lifesciences Private LimitedU24290GJ2020PTC117407
Varenyam Biolifesciences Private LimitedU24290GJ2022PTC133332

To see the full group structure of Bharat Parenterals Limited, buy the company report.

Employees & EPFO

Bharat Parenterals Limited has a workforce of 396 employees on its EPFO records as of Dec 08, 2025, across 1 active EPFO establishment.

Employee count
396
Active EPFO establishments
1
Employee growth
3.66%

GST

Bharat Parenterals has 3 GST registrations: 1 active and 2 cancelled or inactive.

Total GSTINs
3
Active
1
Cancelled / inactive
2
GSTINStateStatusRegistered on
24AAACB8636N1ZEGujaratActive01 Jul 2017

To see the full GST registrations and return filing status of Bharat Parenterals Limited, buy the company report.

Recent activity

Bharat Parenterals Limited has 24 board changes on record since 1992: 15 appointments and 9 cessations. The latest: Alkesh Jayantilal Shah was appointed as Director on 28 Jul 2025.

Filing
Bharat Parenterals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 1.39 Cr with Charge ID 101250276 was registered on 16 Feb 2026.
Charges
A charge with Sidbi amounted to Rs. 12.00 Cr with Charge ID 101209961 was registered on 17 Dec 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.13 Cr with Charge ID 101189310 was registered on 26 Nov 2025.
AGM
Bharat Parenterals Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Charges
A charge with Axis Bank Limited of Rs. 84.36 Cr registered on 04 Feb 2008 with Charge ID 10120617 was modified on 13 Aug 2025.
Appointed
Alkesh Jayantilal Shah was appointed as Director.
Charges
A charge registered on 26 Jun 2024 via Charge ID 100950684 with Others was fully satisfied on 02 Jul 2025.
Appointed
Sharmin Nareshkumar Soni was appointed as Company Secretary.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.22 Cr with Charge ID 101015285 was registered on 16 Dec 2024.
Charges
A charge registered on 01 Dec 2023 via Charge ID 100824867 with Hdfc Bank Limited was fully satisfied on 12 Dec 2024.
Charges
A charge with Others of Rs. 30.00 Cr registered on 26 Jun 2024 with Charge ID 100950684 was modified on 27 Nov 2024.

84 earlier events are in the company report.

News

Bharat Parentals: Innoxel Lifesciences Starts Commercial Sales In The U.S. With First Product Launched On October 20, 2026; More CMO Launches Anticipated In FY27.
21 Oct 2026 · Exchange Update

Frequently asked questions

Bharat Parenterals is an active public limited company based in Vadodara, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 September 1992 (34+ years old) and is registered under CIN L24231GJ1992PLC018237. Listed on BSE: 541096 and NSE: BPLPHARMA.

Bharat Parenterals reported revenue of ₹345.43 Cr for FY 2025-26 (up 1.5% YoY) based on consolidated financials.

Bharat Parenterals has 6 current directors:

The latest financial statements of Bharat Parenterals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Bharat Parenterals is 24AAACB8636N1ZE, registered in Gujarat. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.

The CIN (Corporate Identification Number) of Bharat Parenterals is L24231GJ1992PLC018237. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Bharat Parenterals is a listed company as per MCA records. Its shares are listed on both BSE (code: 541096) and NSE (symbol: BPLPHARMA).

Bharat Parenterals has 157 court cases on record: 120 filed by the company and 38 filed against it. 40 are pending. Most are in the district courts.

Bharat Parenterals was incorporated on 03 September 1992, making it 34+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Bharat Parenterals has 1 deal on record (1 market trade); the latest was in February 2025.

The peers of Bharat Parenterals by revenue are Kopran Research Laboratories Limited, Geltec Private Limited, Mepro Pharmaceuticals Private Limited, Geno Pharmaceuticals Private Limited, Sparsh Bio-Tech Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Alkesh Jayantilal Shah was appointed as Director on 28 Jul 2025. Sharmin Nareshkumar Soni was appointed as Company Secretary on 07 May 2025. Sanjay Parasmal Shah ceased to be Additional Director on 30 Sep 2021. Bharat Parenterals has 24 board changes on record in total.